{"id":252,"date":"2022-12-09T17:39:20","date_gmt":"2022-12-09T15:39:20","guid":{"rendered":"https:\/\/www.everpharma.com\/ita\/products\/bortezomib\/"},"modified":"2022-12-09T17:39:20","modified_gmt":"2022-12-09T15:39:20","slug":"bortezomib","status":"publish","type":"product","link":"https:\/\/www.everpharma.com\/ita\/en\/products\/bortezomib\/","title":{"rendered":"Bortezomib"},"content":{"rendered":"\n<div class=\"wp-block-group meta\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Dosage Form<\/strong><\/td><td>Solution for injection<\/td><\/tr><tr><td><strong>Strength<\/strong><\/td><td>2.5 mg\/ml<\/td><\/tr><tr><td><strong>Strength per Unit<\/strong><\/td><td>2.5 mg\/1.0 ml, 3.5 mg\/1.4 ml<\/td><\/tr><tr><td><strong>ATC Code <\/strong><\/td><td>L01XG01<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Antineoplastic agents, other antineoplastic agents<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Bortezomib EVER Pharma as monotherapy or in combination with pegylated liposomal doxorubicin<br>or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma<br>who have received at least 1 prior therapy and who have already undergone or are unsuitable for<br>haematopoietic stem cell transplantation.<br>Bortezomib EVER Pharma in combination with melphalan and prednisone is indicated for the<br>treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-<br>dose chemotherapy with haematopoietic stem cell transplantation.<br>Bortezomib EVER Pharma in combination with dexamethasone, or with dexamethasone and<br>thalidomide, is indicated for the induction treatment of adult patients with previously untreated<br>multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell<br>transplantation.<br>Bortezomib EVER Pharma in combination with rituximab, cyclophosphamide, doxorubicin and<br>prednisone is indicated for the treatment of adult patients with previously untreated mantle cell<br>lymphoma who are unsuitable for haematopoietic stem cell transplantation.<\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-base-font-size wp-block-paragraph\"><em>Bortezomib EVER Pharma is a prescription medication. Information for healthcare professionals only.<br>See the Summary of Product Characteristics for full information about the medication.<\/em><\/p>\n\n\n\n<p class=\"has-base-font-size wp-block-paragraph\"><em>Bortezomib EVER Pharma will not be distributed in Germany.<\/em><\/p>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dosage Form Solution for injection Strength 2.5 mg\/ml Strength per Unit 2.5 mg\/1.0 ml, 3.5 mg\/1.4 ml ATC Code L01XG01 Drug Class Antineoplastic agents, other antineoplastic agents Indication Bortezomib EVER Pharma as monotherapy or in combination with pegylated liposomal doxorubicinor dexamethasone is indicated for the treatment of adult patients with progressive multiple myelomawho have received &hellip; <a href=\"https:\/\/www.everpharma.com\/ita\/en\/products\/bortezomib\/\">Continued<\/a><\/p>\n","protected":false},"featured_media":0,"template":"","class_list":["post-252","product","type-product","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bortezomib - EVER Pharma Italy<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.everpharma.com\/ita\/en\/products\/bortezomib\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bortezomib - EVER Pharma Italy\" \/>\n<meta property=\"og:description\" content=\"Dosage Form Solution for injection Strength 2.5 mg\/ml Strength per Unit 2.5 mg\/1.0 ml, 3.5 mg\/1.4 ml ATC Code L01XG01 Drug Class Antineoplastic agents, other antineoplastic agents Indication Bortezomib EVER Pharma as monotherapy or in combination with pegylated liposomal doxorubicinor dexamethasone is indicated for the treatment of adult patients with progressive multiple myelomawho have received &hellip; Continued\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.everpharma.com\/ita\/en\/products\/bortezomib\/\" \/>\n<meta property=\"og:site_name\" content=\"EVER Pharma Italy\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/ita\\\/en\\\/products\\\/bortezomib\\\/\",\"url\":\"https:\\\/\\\/www.everpharma.com\\\/ita\\\/en\\\/products\\\/bortezomib\\\/\",\"name\":\"Bortezomib - EVER Pharma Italy\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/ita\\\/en\\\/#website\"},\"datePublished\":\"2022-12-09T15:39:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/ita\\\/en\\\/products\\\/bortezomib\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.everpharma.com\\\/ita\\\/en\\\/products\\\/bortezomib\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/ita\\\/en\\\/products\\\/bortezomib\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.everpharma.com\\\/ita\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Products\",\"item\":\"https:\\\/\\\/www.everpharma.com\\\/ita\\\/en\\\/products\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Bortezomib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/ita\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.everpharma.com\\\/ita\\\/en\\\/\",\"name\":\"EVER Pharma Italy\",\"description\":\"Dedicated to Health.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.everpharma.com\\\/ita\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bortezomib - EVER Pharma Italy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.everpharma.com\/ita\/en\/products\/bortezomib\/","og_locale":"en_US","og_type":"article","og_title":"Bortezomib - EVER Pharma Italy","og_description":"Dosage Form Solution for injection Strength 2.5 mg\/ml Strength per Unit 2.5 mg\/1.0 ml, 3.5 mg\/1.4 ml ATC Code L01XG01 Drug Class Antineoplastic agents, other antineoplastic agents Indication Bortezomib EVER Pharma as monotherapy or in combination with pegylated liposomal doxorubicinor dexamethasone is indicated for the treatment of adult patients with progressive multiple myelomawho have received &hellip; Continued","og_url":"https:\/\/www.everpharma.com\/ita\/en\/products\/bortezomib\/","og_site_name":"EVER Pharma Italy","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.everpharma.com\/ita\/en\/products\/bortezomib\/","url":"https:\/\/www.everpharma.com\/ita\/en\/products\/bortezomib\/","name":"Bortezomib - EVER Pharma Italy","isPartOf":{"@id":"https:\/\/www.everpharma.com\/ita\/en\/#website"},"datePublished":"2022-12-09T15:39:20+00:00","breadcrumb":{"@id":"https:\/\/www.everpharma.com\/ita\/en\/products\/bortezomib\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.everpharma.com\/ita\/en\/products\/bortezomib\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.everpharma.com\/ita\/en\/products\/bortezomib\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.everpharma.com\/ita\/en\/"},{"@type":"ListItem","position":2,"name":"Products","item":"https:\/\/www.everpharma.com\/ita\/en\/products\/"},{"@type":"ListItem","position":3,"name":"Bortezomib"}]},{"@type":"WebSite","@id":"https:\/\/www.everpharma.com\/ita\/en\/#website","url":"https:\/\/www.everpharma.com\/ita\/en\/","name":"EVER Pharma Italy","description":"Dedicated to Health.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.everpharma.com\/ita\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.everpharma.com\/ita\/en\/wp-json\/wp\/v2\/product\/252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.everpharma.com\/ita\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/www.everpharma.com\/ita\/en\/wp-json\/wp\/v2\/types\/product"}],"wp:attachment":[{"href":"https:\/\/www.everpharma.com\/ita\/en\/wp-json\/wp\/v2\/media?parent=252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}